RxDoctor Payments Data

Shannon Mathis, NP

Nurse Practitioner · Wilmington, NCNPI 1013472232

Payments from drug & device makers

$3,272in general payments, 2019–2025

Across 139 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547
  • Novo Nordisk$495
  • AstraZeneca$449
  • Lilly USA, LLC$219
  • E.r. Squibb & Sons, L.L.C.$199
  • Pfizer$144
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,22999%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,272 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$88,874
Medicare patients
424
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$35,406
MounjaroTirzepatide28$34,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,838
EliquisApixaban13$17,749
JardianceEmpagliflozin23$16,764
FarxigaDapagliflozin Propanediol14$16,275
LinzessLinaclotide11$12,037
Estradiol15$1,920
SynthroidLevothyroxine Sodium20$1,128
Ventolin HfaAlbuterol Sulfate20$1,098
Atorvastatin Calcium70$1,079
Rosuvastatin Calcium106$971
Fluticasone Propionate101$967
Albuterol Sulfate HfaAlbuterol Sulfate28$870
Bupropion XlBupropion Hcl35$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$495$35,40630 claims
Lilly USA, LLCMounjaro$219$34,71728 claims
GSKTrelegy Ellipta$57$18,83820 claims
PfizerEliquis$144$17,74913 claims
Boehringer IngelheimJardiance$111$16,76423 claims
AstraZenecaFarxiga$449$16,27514 claims
AbbVieLinzess, Synthroid$547$13,16431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →